Abstract:Objective To study if the protective effect of dexmedetomidine on the pyohemia-associated delirium is through the cholinergic anti-inflammatory pathway.Methods Sixty male adult C57 mice were randomly divided into five groups (n=12 each): saline group (group C),dexmedetomidine (DEX) alone group (group DEX),endotoxemia (LPS) group (group LPS),dexmedetomidine protection group (group LPS+DEX) and alpha-bungarotoxin (α-BGT) group (group α-BGT).Each group were assigned to two subunits (n=6 each),mice in subunit one were sacrificed after examining the open field test,mice in subunit two were sacrificed after testing the novel object recognition.The level of inflammatory factors were measured by enzyme-linked immune sorbent assay (ELISA).The ultrastructure changes of the hippocampus in mice were observed by transmission electron microscopy.Results Compared with group C,there are no significant differences in group DEX.Dexmedetomidine significantly attenuated the delirious syndrome after LPS induced endotoxemia,however,the effect of dexmedetomidine disappeared in group α-BGT,and the syndrome of cognitive dysfunction in LPS group were more severe than that in group α-BGT.(1) The open field test show that there are no significant differences each group with that before model establishment;after the models were established 24 h,compared with group C,group LPS show that the abilities of cognition to new environment、learning and memory were decreasing,the tension is increasing.preemptive administration of dexmedetomidine significantly attenuated the delirious syndrome after LPS induced endotoxemia;however,preemptive administration of dexmedetomidine failed to control the delirious syndrome in group α-BGT.(2) The novel object recognition testshow that compared to group C,the ability of exploring the novel object is decreasing;preemptive administration of dexmedetomidine significantly improve the exploration ability,however,preemptive administration of dexmedetomidine failed to control the delirious syndrome in group α-BGT.(3) The results of ELISA show that: Compared with group C,the concentrations of tumor necrosis factor-α (TNF-α) and interleukin (IL)-1β in serum and Hippocampus were all increased in LPS groups[Serum (ng/L) TNF-α: 794.80±93.99 vs.23.60±3.03,IL-1β: 148.49±24.80 vs.64.55±5.13,Hippocampus (pg/mg·prot) TNF-α: 176.14±11.25 vs.6.71±0.49,IL-1β: 50.61±5.86 vs.16.73±1.15,P=0.000],compared with group LPS,the concentrations were all significantly decreased in group LPS+DEX[Serum (ng/L) TNF-α: 184.44±26.58 vs.794.80±93.99,IL-1β: 77.43±10.75 vs.148.49±24.80,Hippocampus (pg/mg·prot) TNF-α: 64.83±13.09 vs.176.14±11.25,IL-1β: 17.97±2.26 vs.50.61±5.86,P=0.000].However,α-BGT can reverse the protective effect[Serum (ng/L): TNF-α: 812.31±86.25 vs.184.44±26.58,IL-1β: 156.42±17.94 vs.77.43±10.75,Hippocampus (pg/mg·prot) TNF-α: 181.94±8.69 vs.64.83±13.09,IL-1β: 52.10±5.59 vs.17.97±2.26,P=0.000].TEM shown that the histopathological damage of hippocampus tissue in group LPS and α-BGT were heavier,which in group LPS+DEX was reversed partially.Conclusion Central alpha-2 agonist dexmedetomidine attenuates sepsis-associated delirium syndrome likely through activating cholinergic anti-inflammatory pathway and inhibiting the inflammatory responses in serum and brain.

Dexmedetomidine Exerts an Anti-inflammatory Effect Via Α2 Adrenoceptors to Prevent Lipopolysaccharide-induced Cognitive Decline in Mice

Dexmedetomidine Exerts an Anti-inflammatory Effect via α2 Adrenoceptors to Prevent Lipopolysaccharide-induced Cognitive Decline in Mice.

Dexmedetomidine Exerts an Anti-Inflammatory Effect Via Α2 Adrenoceptors to Alleviate Cognitive Dysfunction in 5xfad Mice.

Dexmedetomidine Controls Systemic Cytokine Levels Through the Cholinergic Anti-inflammatory Pathway

Dexmedetomidine attenuates pyohemia-associated delirium in mice through the cholinergic anti-inflammatory pathway

Dexmedetomidine Attenuates Lipopolysaccharide-Induced Inflammation Through Macrophageal IL-10 Expression Following Α7 Nachr Activation

Dexmedetomidine Ameliorated Cognitive Dysfunction Induced by Intestinal Ischemia Reperfusion in Mice with Possible Relation to the Anti-inflammatory Effect Through the Locus Coeruleus Norepinephrine System

Dexmedetomidine alleviates cognitive impairment by reducing blood-brain barrier interruption and neuroinflammation via regulating Th1/Th2/Th17 polarization in an experimental sepsis model of mice

Dexmedetomidine Attenuates Lipopolysaccharide-Induced Proinflammatory Response in Primary Microglia.

Dexmedetomidine ameliorates memory impairment in sleep-deprived mice

Effects of dexmedetomidine on cognitive dysfunction and neuroinflammation via the HDAC2/HIF‐1α/PFKFB3 axis in a murine model of postoperative cognitive dysfunction

Dexmedetomidine Attenuates Inflammatory Reaction in the Lung Tissues of Septic Mice by Activating Cholinergic Anti-Inflammatory Pathway

Dexmedetomidine Attenuates Sevoflurane‑induced Neurocognitive Impairment Through Α2‑adrenoceptors

Dexmedetomidine Inhibits LPS-induced Proinflammatory Responses Via Suppressing HIF1α-dependent Glycolysis in Macrophages

Dexmedetomidine inhibits lipopolysaccharide-in duced inflammatory response in hippocampal astrocytes in vitro

Dexmedetomidine Acts Via the JAK2/STAT3 Pathway to Attenuate Isoflurane-Induced Neurocognitive Deficits in Senile Mice

Dexmedetomidine ameliorates postoperative cognitive dysfunction by inhibiting Toll‐like receptor 4 signaling in aged mice

Dexmedetomidine Activates Akt, STAT6 and IRF4 Modulating Cytoprotection and Macrophage Anti-Inflammatory Phenotype Against Acute Lung Injury in Vivo and in Vitro

Dexmedetomidine Inhibits Neuroinflammation by Altering Microglial M1/M2 Polarization Through MAPK/ERK Pathway

Dexmedetomidine Ameliorates Postoperative Cognitive Dysfunction in Aged Mice

Dexmedetomidine Alleviates Lipopolysaccharide-Induced Hippocampal Neuronal Apoptosis Via Inhibiting the P38 MAPK/c-Myc/CLIC4 Signaling Pathway in Rats